How Testosterone Enanthate Affects HDL Cholesterol

Testosterone suppresses HDL cholesterol through well-characterised hepatic mechanisms:

1. Hepatic lipase activation: Testosterone (and all androgens) upregulate hepatic lipase, the enzyme responsible for catabolising HDL particles. Increased hepatic lipase activity accelerates HDL clearance from the bloodstream, reducing circulating HDL levels.
2. CETP modulation: Androgens may increase cholesteryl ester transfer protein (CETP) activity, which transfers cholesterol from HDL to LDL and VLDL particles, further depleting HDL.
3. SR-BI receptor effects: Androgen receptor activation alters scavenger receptor class B type I (SR-BI) expression in the liver, affecting HDL-mediated reverse cholesterol transport.
4. Partial estradiol offset: Unlike non-aromatising steroids, testosterone converts to estradiol, which has HDL-protective effects. This aromatisation partially counterbalances the direct androgenic suppression of HDL, which is why testosterone is less lipid-toxic than trenbolone or oral steroids that do not aromatise (or that actively suppress estradiol).

The net effect at TRT doses is a modest HDL reduction that is generally clinically manageable. At supraphysiological doses, the effect becomes more pronounced and clinically significant.

TRT doses (100-200 mg/week):

• HDL typically decreases 10-20% from baseline
• A pre-TRT HDL of 50 mg/dL might drop to 40-45 mg/dL
• LDL may remain stable or increase mildly
• The total cholesterol/HDL ratio worsens modestly
• This level of change is considered clinically acceptable for most men

Moderate supraphysiological doses (300-500 mg/week):

• HDL typically decreases 20-35%
• A pre-cycle HDL of 50 mg/dL might drop to 32-40 mg/dL
• LDL often increases proportionally
• The lipid profile becomes meaningfully atherogenic

High doses (500-1000+ mg/week):

• HDL can decrease 30-40% or more
• Combined with other compounds (especially oral steroids), HDL may drop below 25 mg/dL
• At this level, reverse cholesterol transport is significantly impaired

Timeline: HDL suppression begins within 1-2 weeks and reaches maximum effect at 4-8 weeks. The suppression persists for as long as testosterone is administered at supraphysiological doses. On TRT doses, a new equilibrium is reached that is modestly lower than baseline.

Important context: Testosterone's lipid impact is significantly milder than trenbolone's (50-70% HDL reduction) or oral steroids' (40-60% HDL reduction). This is partly because testosterone aromatises to estradiol, which has cardioprotective and HDL-preserving effects.

Baseline: Full lipid panel before starting testosterone. This is your reference point for all future comparisons.

TRT patients: Check lipids at 3 months, then every 6-12 months if stable.

Supraphysiological doses (blast cycles): Check lipids at week 4-6 of the cycle. If HDL drops below 30 mg/dL, consider dose reduction or cycle shortening.

Post-cycle/cruise: Recheck lipids 6-8 weeks after returning to TRT dose or after discontinuation.

Advanced markers: ApoB is a more informative marker of cardiovascular risk than LDL alone. If available, include ApoB in lipid panels, especially during blast cycles.

Risk stratification: Men with family history of premature cardiovascular disease, pre-existing dyslipidemia, or other cardiovascular risk factors (smoking, hypertension, diabetes) should monitor lipids more frequently and maintain lower thresholds for intervention.

At TRT doses (HDL drop of 10-20%):

• Cardiovascular exercise: 150+ minutes per week of moderate-intensity cardio is the single most effective intervention for supporting HDL on TRT
• Omega-3 fatty acids 2-4 g EPA/DHA daily for triglyceride reduction and endothelial health
• Maintain a diet rich in monounsaturated fats (olive oil, avocados, nuts)
• For most men, the modest HDL reduction on TRT is manageable with lifestyle alone

At supraphysiological doses (HDL drop of 20-40%):

• Increase cardio volume during blast cycles; consider 200+ minutes per week
• Omega-3 fatty acids 3-5 g EPA/DHA daily
• Citrus bergamot 500-1000 mg/day
• Niacin (extended-release) 500-1000 mg/day may raise HDL by 10-20%
• Keep blast cycles as short as practical to limit cumulative lipid damage

Compound selection considerations:

• Adding a non-aromatising compound (trenbolone, stanozolol) dramatically worsens the lipid impact beyond testosterone alone
• If HDL is a concern, favour aromatising compounds over non-aromatising ones; the estradiol produced helps preserve HDL
• Oral steroids added to a testosterone base cause the most severe lipid deterioration

Long-term perspective: Lipid damage from testosterone is cumulative across years of use. Men who maintain chronically suppressed HDL (below 35 mg/dL) across multiple blast cycles accumulate atherosclerotic plaque regardless of how "healthy" they feel. Coronary artery calcium (CAC) scoring every 2-3 years is recommended for long-term steroid users over 35 to detect subclinical atherosclerosis.